Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03047395 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,170
- Enrollment target
NCT03047395 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 2,170 participants.
The verdict
NCT03047395, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,170 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.
Interventions
- BIOLOGICAL risankizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,170 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2023-11-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03047395
The ClinicalTrials.gov registry entry for NCT03047395 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which risankizumab is the first listed.
NCT03047395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03047395 about?
NCT03047395 is a clinical study titled "A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )". The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis.
What is the current status of trial NCT03047395?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,170 participants. The study started on 2017-02-27. Estimated completion is 2023-11-29.
What interventions are being tested in trial NCT03047395?
The interventions under investigation include: risankizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03047395?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.